Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | SCN4A | P35499 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578371 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| SCHEMBL16334289 | 1.00 | AOC3 (0.44) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| Hydrochloric Acid SCHEMBL27833791 | 0.98 | IDO1 (0.45) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| Hydrochloric Acid SCHEMBL27833790 | 0.98 | IDO1 (0.45) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| SCHEMBL2670037 | 0.86 | AOC3 (0.41) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| SCHEMBL93693 | 0.81 | CYP1A2 (0.41) | SCN4ASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8470594 | 0.79 | ESR1 (0.43) | SCN4ASLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL16563617 | 0.79 | DPP4 (0.41) | SCN4ASLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL5460859 | 0.79 | SCN4A (0.53) | AOC3IDO1TDO2SCN4ASLC6A2 | |
| SCHEMBL7770297 | 0.79 | CYP1A2 (0.63) | AOC3SCN4ASLC6A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016041201-A1 | THIENOPYRIMIDINE DERIVATIVES AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 上海创诺医药集团有限公司 | 2016-03-24 | — | — | WO | disclosed |
| EP-2365752-B1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8486951-B2 | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-8278331-B2 | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-10-02 | — | — | US | disclosed |
| CN-102256493-A | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS LLC | 2011-11-23 | — | — | CN | disclosed |
| EP-2365752-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, Llc (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
| CN-1434808-A | Novel branched substituted amino derivatives of 3-amino-1-phemyl-1H[1,2,4]triazo, methods for producing them and pharmaceutica compositions containing them | SANOFI SYNTHELABO (FR) | 2003-08-06 | — | — | CN | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1242389-A2 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2002-09-25 | — | — | EP | disclosed |
| CN-1370154-A | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI SYNTHELABO (FR) | 2002-09-18 | — | — | CN | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001044207-A2 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | AOC3 3675/4885IDO1 2773/4885TDO2 1391/4885 |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | AOC3 4057/4885IDO1 3754/4885TDO2 4166/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | AOC3 3943/4885IDO1 3645/4885TDO2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.